Post Profile






High response rate in phase I/II paediatric brain cancer trial

(European Society for Medical Oncology) A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Clinical Trial Analysis Suggests Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer

Health : Newswise Medical News

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Pazopanib Shows Promise In Phase II Trial For Relapsed/Refractory Urothelial Cancer

Health : Medical News Today

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (...

Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

High response rate in phase I/II pediatric brain cancer trial sets stage for combination therapy with higher response, lower toxicity

Diseases & Conditions / Cancer : ScienceDaily: Cancer

A high response rate with a single drug in a phase I/II trial of pediatric brain tumor has set the stage for combination therapy with higher response and lower toxicity, researchers report.

Comments


Copyright © 2016 Regator, LLC